Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial

BACKGROUND: An urgent need exists to rapidly screen potential therapeutics for severe COVID-19 or other emerging pathogens associated with high morbidity and mortality. METHODS: Using an adaptive platform design created to rapidly evaluate investigational agents, hospitalised patients with severe CO...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981330/
https://www.ncbi.nlm.nih.gov/pubmed/36883141
http://dx.doi.org/10.1016/j.eclinm.2023.101889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981330/
https://www.ncbi.nlm.nih.gov/pubmed/36883141
http://dx.doi.org/10.1016/j.eclinm.2023.101889

Ejemplares similares